Presentation is loading. Please wait.

Presentation is loading. Please wait.

Larry L. Wood Corporate Vice President Edwards Lifesciences

Published byBernadette Horn Modified over 6 years ago

Similar presentations

Presentation on theme: "Larry L. Wood Corporate Vice President Edwards Lifesciences"— Presentation transcript:

1 Larry L. Wood Corporate Vice President Edwards Lifesciences
Update on the Commercial Launch of TAVR in the US: Site Selection, Training, Clinical Indications, Case Volumes & Clinical Outcomes Larry L. Wood Corporate Vice President Edwards Lifesciences

2 Disclosure Statement of Financial Interest
I, Larry L. Wood, DO have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

3 FDA-Approved US Indications for TAVR
November 2, 2011 October 19, 2012 3

4 Edwards US TAVR Site Activation Program Overview
Selected Training Begins Patient Selection ~5 Cases Required for Fundamentals Room & Heart Team Readiness Follow Up Fundamentals Training Patients Screened Proctoring Begins Proctor Independence

5 Edwards TAVR Fundamentals Training Program
TF Fundamentals Program TA Fundamentals Program DAY 1 DAY 1 DAY 2 TF Procedural Deep Dive– How to avoid, detect, manage PARTNER Data Review Technology Overview Multidisciplinary Team Setup PARTNER A Overview Technology Overview Patient Screening Taped Live-Case Device Demo & Simulation Pt Case Presentations Pt Screening Anesthesia Management Working Lunch Each site presents 2 cases TA Procedural Deep Dive Tips and Tricks Complication Mgmt, Best Practices Working Lunch Panel Q & A Procedure Room Setup Equipment, Staff Case Observation “Live” taped cases Procedural Deep Dive Device Demo & Simulation Pt Case Presentations CT and Echo Workshop

6 TAVR US Commercial Sites Trained
169 New TF Sites 103 New TA Sites New sites only: Excludes sites from The PARTNER Trial 6

7 1,450+ US HEART Team Members Trained
HEART Teams 457 ICs 394 CTS’ 152 Echocardiographers 87 Anesthesiologists 51 OR/CCL staff members Support Teams Valve clinic coordinators Nurses Administrators Radiologists Cardiologists Vascular surgeons Valve clinic staff members Perfusionists Total: 314 support staff Minimum of 2 each per site New sites only: Excludes sites from The PARTNER Trial

8 US Commercial Sites Are Experienced Interventional & Surgical Centers
PCI sAVR BAV PFO ASD/ VSD Perc. Mitral repair EVAR TEVAR LVAD 1,463 175 20* 23* 16* 12* 53* 13* *Average as-reported annual procedural volume at sites performing given procedure

9 US Commercial TAVR Cases
More Than 5,000 Patients Treated Launch-to-Date

10 4 – 6 Cases To Independence (US Commercial Average)
144 TF proctor-independent sites 26 TA proctor-independent sites New sites only: Excludes sites from The PARTNER Trial

11 Edwards Is Committed To Partnering For Procedural Success
SAPIEN-specific 3D reconstruction and measurement program Annular sizing & shape analysis Calcification location & loads Access path diagnostics Recommendations for obtaining perpendicularity 11

12 Post-Approval and Indication Expansion Efforts
PAS2 – Post-Market Surveillance Tracking over 3,000 patients for 5 years Annual follow-up -- including echo TVT Registry Required by CMS for reimbursement All patients enrolled in US at all TAVR sites Allows for long term follow-up STS & ACC IDEs Alternative Access on-label & reimbursable for non-operable patients Valve in Valve and Alternate Access for high-risk patients pending

13 Our Driving Force

Download ppt "Larry L. Wood Corporate Vice President Edwards Lifesciences"

Similar presentations

The Execution and Management of a Complex Clinical Trial Elizabeth K. Walsh, RN ECTSS 2013 Conflicts of Interest Advisory Board for TAVR Administrators.

The Execution and Management of a Complex Clinical Trial Elizabeth K. Walsh, RN ECTSS 2013 Conflicts of Interest Advisory Board for TAVR Administrators.
Developing the Nurse Coordinator Role

Developing the Nurse Coordinator Role
Starting an Extraction Program Getting your ducks in a row… Samir Saba, MD, FHRS Director, Cardiac Electrophysiology University of Pittsburgh Medical Center.

Starting an Extraction Program Getting your ducks in a row… Samir Saba, MD, FHRS Director, Cardiac Electrophysiology University of Pittsburgh Medical Center.
Sixth Annual Meeting March 12, 2012 8:00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.

Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.
Disclosure Statement of Financial Interest I, (insert name),I, (insert name), DO NOT have a financial interest/arrangement or affiliation with one or more.

Disclosure Statement of Financial Interest I, (insert name),I, (insert name), DO NOT have a financial interest/arrangement or affiliation with one or more.
Utilizing Registries and Guidelines in CV Care: Have They Improved Outcomes & Decreased Cost? Amy Simone, PA-C Emory University Hospital Structural Heart.

Utilizing Registries and Guidelines in CV Care: Have They Improved Outcomes & Decreased Cost? Amy Simone, PA-C Emory University Hospital Structural Heart.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Howard C. Herrmann, MD on behalf of The PARTNER II Trial Investigators SAPIEN 3: Evaluation of a Balloon- Expandable.

TCT 2015 | San Francisco | October 15, 2015 Howard C. Herrmann, MD on behalf of The PARTNER II Trial Investigators SAPIEN 3: Evaluation of a Balloon- Expandable.
REGISTRY APPROACHES in DEVICE SURVEILLANCE Fred H. Edwards, MD Director, STS Research Center Emeritus Professor, University of Florida.

REGISTRY APPROACHES in DEVICE SURVEILLANCE Fred H. Edwards, MD Director, STS Research Center Emeritus Professor, University of Florida.
Twelve Months and Beyond: Long-Term Results of the Direct Flow Medical Repositionable and Retrievable Pericardial Valve for Percutaneous Aortic Valve Replacement.

Twelve Months and Beyond: Long-Term Results of the Direct Flow Medical Repositionable and Retrievable Pericardial Valve for Percutaneous Aortic Valve Replacement.
1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.

1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.
Lessons from PARTNER I (A & B) CRT, Washington DC, Feb 5, 2012

Lessons from PARTNER I (A & B) CRT, Washington DC, Feb 5, 2012
VSD post TAVR: Mechanisms, Presentation and Management

VSD post TAVR: Mechanisms, Presentation and Management
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.

Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.
Rachel Neubrander, PhD Division of Cardiovascular Devices

Rachel Neubrander, PhD Division of Cardiovascular Devices
Lessons Learned from the TVT Registry Experience

Lessons Learned from the TVT Registry Experience
LAAC: What Does the Post Marketing Data Tell Us?

LAAC: What Does the Post Marketing Data Tell Us?
Patient Eligibility for Commercial TAVR in the US

Patient Eligibility for Commercial TAVR in the US
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.

Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.

Similar presentations

Ads by Google